Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment

被引：0
|
作者：
Rexer, H. [1 ,3 ]
Ohlmann, C. -H. [2 ]
Grimm, M. -O.
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Deutsch Krebsgesellschaft eV, Arbeitsgemeinschaft Urol Onkol, Berlin, Germany
[3] AUO Geschaftsstelle Frau Heidrun Rexer ViSdP, MeckEvidence H Rexer Seestr 11, D-17252 Schwarz, Germany
来源：
UROLOGIE | 2023年 / 62卷 / 03期
关键词：
D O I：
10.1007/s00120-023-02056-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 339
页数：2
相关论文
共 50 条
  • [31] Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
    Doisy, Laure
    Cimier, Arnaud
    Adypagavane, Aurelien
    Walz, Jochen
    Marquette, Thibault
    Maubon, Thomas
    Rybikowski, Stanislas
    Fakhfakh, Sami
    Loverde, Kevin
    Mottet, Nicolas
    Irani, Jacques
    Lechevallier, Eric
    Rossi, Dominique
    Gravis, Gwenaelle
    Pignot, Geraldine
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2021, 38 (01) : 1633 - 1638
  • [32] Secondary Prevention of non-muscle invasive Bladder Cancer (NMIBC): Randomized Phase 2 Trial of Erdafitinib versus intravesical Chemotherapy of investigator's Choice in Patients with High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) and Recurrence and post FGFR Mutations or Fusions Immunotherapy with Bacillus Calmette-Guerin (BCG) (THOR-2) - AB 78/21 of the AUO
    Rexer, Heidrun
    Kramer, Mario
    Merseburger, Axel S.
    AKTUELLE UROLOGIE, 2022, 53 (04) : 314 - 315
  • [33] Predictors of response to BCG therapy in non-muscle invasive bladder cancer
    Radovanovic, Milan
    Petrovic, Milos
    Santric, Veljko
    Zubelic, Aleksa
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2022, 150 (1-2) : 113 - 116
  • [34] Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC).
    Halachmi, Sarel
    Leibovitch, Ilan
    Zisman, Amnon
    Stein, Avi
    Benjamin, Shalva
    Sidi, Ami
    Knickerbocker, Ron
    Limor, Michal
    Moore, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Secondary Prevention of Non-Muscle Invasive Bladder Cancer (NMIBC)
    Rexer, H.
    Kramer, M.
    Merseburger, A.
    UROLOGE, 2022, 61 (04): : 467 - 468
  • [36] Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC
    Loriot, Yohann
    Roupret, Morgan
    BULLETIN DU CANCER, 2020, 107 (05) : S49 - S55
  • [37] Diagnosis and management of severe adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC)
    Neuzillet, Yann
    Roupret, Morgan
    Larre, Stephane
    Irani, Jacques
    Davin, Jean-Louis
    Moreau, Jean-Luc
    Pfister, Christian
    PRESSE MEDICALE, 2013, 42 (7-8): : 1100 - 1108
  • [38] SEQUENTIAL INTRAVESICAL GEMCITABINE AND DOCETAXEL FOR BCG-NAIVE HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
    McElree, Ian M.
    Steinberg, Ryan L.
    Martin, Alexander C.
    Richards, Jordan
    Mott, Sarah L.
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E488 - E488
  • [39] MEASURING DISEASE AND TREATMENT-RELATED SYMPTOMS AND HRQOL IMPACTS IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) USING THE EORTC QLQ-C30 AND NMIBC-24: QUALITATIVE LITERATURE REVIEW AND GAP ANALYSIS
    Mason, B.
    Eccleston, A.
    Ayala, Nunes L.
    Chandrasekar, S.
    Leventi, A.
    Gater, A.
    Chang, J.
    VALUE IN HEALTH, 2024, 27 (06) : S327 - S328
  • [40] NON-MUSCLE INVASIVE BLADDER CANCER RESISTANT TO BCG
    Turker, Polat
    Turkeri, Levent
    ARCHIVOS ESPANOLES DE UROLOGIA, 2013, 66 (09): : 833 - 840
12345